Phase III randomized, double-blind, active-controlled study of momelotinib versus ruxolitinib in patients with myelofibrosis.

被引：0
作者：
Winton, Elliott F.
Devos, Timothy
Oh, Stephen T.
Platzbecker, Uwe
Wadleigh, Martha
Jun, Susie
Lee, Peter
Deng, Wei
Gupta, Vikas
机构：
[1] Emory Univ, Sch Med, Atlanta, GA USA
[2] Univ Ziekenhuizen Leuven UZ Leuven, Leuven, Belgium
[3] Washington Univ, St Louis, MO USA
[4] TUD, Univ Hosp Carl Gustav Carus, Dresden, Germany
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] Gilead Sci Inc, Foster City, CA USA
[7] Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS7101
引用
收藏
页数：1
相关论文
共 50 条
  • [41] THE PRODERM STUDY: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIAL OF IVIG (OCTAGAM 10%) IN PATIENTS WITH ACTIVE DERMATOMYOSITIS
    Aggarwal, R.
    Charles-Schoeman, C.
    Schessl, J.
    Bata-Csorgo, Z.
    Dimachkie, M. M.
    Griger, Z.
    Moiseev, S.
    Oddis, C. V.
    Schiopu, E.
    Vencovsky, J.
    Beck-Mann, I.
    Clodi, E.
    Levine, T.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2023, 41 (02) : 428 - 429
  • [42] A Double-Blind, Randomized, Placebo and Active-Controlled Study of Nebicapone for the Treatment of Motor Fluctuations in Parkinson's Disease
    Ferreira, Joaquim J.
    Rascol, Olivier
    Poewe, Werner
    Sampaio, Cristina
    Rocha, Jose-Francisco
    Nunes, Teresa
    Almeida, Luis
    Soares-da-Silva, Patricio
    [J]. CNS NEUROSCIENCE & THERAPEUTICS, 2010, 16 (06) : 337 - 347
  • [43] Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety
    Markman, John D.
    Bolash, Robert B.
    McAlindon, Timothy E.
    Kivitz, Alan J.
    Pombo-Suarez, Manuel
    Ohtori, Seiji
    Roemer, Frank W.
    Li, David J.
    Viktrup, Lars
    Bramson, Candace
    West, Christine R.
    Verburg, Kenneth M.
    [J]. PAIN, 2020, 161 (09) : 2068 - 2078
  • [44] POSITIVE RESULTS WITH ITI-007 FOR THE TREATMENT OF SCHIZOPHRENIA: A RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE-CONTROLLED PHASE 2 STUDY
    Vanover, Kimberly
    Davis, Robert E.
    Ereshefsky, Larry
    Mates, Sharon
    [J]. SCHIZOPHRENIA RESEARCH, 2014, 153 : S278 - S279
  • [45] Efficacy and Safety of Mildronate for Acute Ischemic Stroke: A Randomized, Double-Blind, Active-Controlled Phase II Multicenter Trial
    Yi Zhu
    Guangyun Zhang
    Jun Zhao
    Deshuai Li
    Xiaodong Yan
    Juanfang Liu
    Xuedong Liu
    Haibo Zhao
    Jielai Xia
    Xiao Zhang
    Zhengyi Li
    Baorong Zhang
    Zongcheng Guo
    Lianyuan Feng
    Zhaodong Zhang
    Fang Qu
    Gang Zhao
    [J]. Clinical Drug Investigation, 2013, 33 : 755 - 760
  • [46] Efficacy and Safety of Mildronate for Acute Ischemic Stroke: A Randomized, Double-Blind, Active-Controlled Phase II Multicenter Trial
    Zhu, Yi
    Zhang, Guangyun
    Zhao, Jun
    Li, Deshuai
    Yan, Xiaodong
    Liu, Juanfang
    Liu, Xuedong
    Zhao, Haibo
    Xia, Jielai
    Zhang, Xiao
    Li, Zhengyi
    Zhang, Baorong
    Guo, Zongcheng
    Feng, Lianyuan
    Zhang, Zhaodong
    Qu, Fang
    Zhao, Gang
    [J]. CLINICAL DRUG INVESTIGATION, 2013, 33 (10) : 755 - 760
  • [47] MANIFEST-2, a Global, Phase 3, Randomized, Double-Blind, Active-Control Study of CPI-0610 and Ruxolitinib vs Placebo and Ruxolitinib in JAKi Treatment-Naive Myelofibrosis Patients
    Mascarenhas, John
    Harrison, Claire
    Luptakova, Katarina
    Wang, Jing
    Colak, Gozde
    Shao, James
    Bobba, Suresh
    Trojer, Patrick
    Humphrey, Jeffrey
    Verstovsek, Srdan
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S363 - S363
  • [48] Manifest-2, a global, phase 3, randomized, double-blind, active-control study of CPI 0610 and ruxolitinib vs. placebo and ruxolitinib in JAKI-treatment-naive myelofibrosis patients
    Mead, Adam
    Mascarenhas, John
    Gerds, Aaron
    Luptakova, Katarina
    Christo, Jessica
    Wang, Jing
    Colak, Gozde
    Shao, James
    Bobba, Suresh
    Trojer, Patrick
    Humphrey, Jeffrey
    Verstovsek, Srdan
    Harrison, Claire
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 101 - 102
  • [49] A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: stage 2 of a phase II trial
    Verstovsek, Srdan
    Talpaz, Moshe
    Wadleigh, Martha
    Isidori, Alessandro
    te Boekhorst, Peter
    Savona, Michael R.
    Bose, Prithviraj
    Pozdnyakova, Olga
    Mesa, Ruben
    El-Galaly, Tarec C.
    O'Sullivan, Jennifer
    Gamel, Katia
    Higgins, Brian
    Katakam, Sudhakar
    Todorov, Boyan
    Trunzer, Kerstin
    Harrison, Claire N.
    [J]. HAEMATOLOGICA, 2024, 109 (06) : 1977 - 1983
  • [50] PHASE 3 RANDOMIZED TRIAL OF MOMELOTINIB VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH MYELOFIBROSIS PREVIOUSLY TREATED WITH RUXOLITINIB: RESULTS OF THE SIMPLIFY-2 STUDY
    Verstovsek, S.
    Vannucchi, A. M.
    Platzbecker, U.
    Cervantes, F.
    Gupta, V.
    Lavie, D.
    Passamonti, F.
    Winton, E. F.
    Dong, H.
    Kawashima, J.
    Maltzman, J. D.
    Kiladjian, J-J.
    Harrison, C. N.
    [J]. HAEMATOLOGICA, 2017, 102 : 320 - 321
12345